Literature DB >> 9950603

Neuropsychological impairment-associated visual field deficits in HIV infection. HNRC Group. HIV Neurobehavioral Research Center.

D J Plummer1, T D Marcotte, P A Sample, T Wolfson, R K Heaton, I Grant, W R Freeman.   

Abstract

PURPOSE: To examine the relationship between loss in peripheral visual sensitivity and neuropsychological functioning in seropositive patients with human immunodeficiency virus (HIV) without infectious retinopathy.
METHODS: Subjects carefully screened for retinal disease and well-matched across demographic and medical variables were grouped according to normal (perimetry-nl) versus abnormal (perimetry-abnl) performance on achromatic automated perimetry and short-wavelength automated perimetry, standard clinical ophthalmologic measures of visual function. All subjects completed a detailed neuropsychological test battery and were classified as impaired or unimpaired, globally and across eight neurocognitive domains. Subjects were also classified according to whether they met diagnostic criteria for minor cognitive/motor disorder (MCMD) or HIV-associated dementia (HAD).
RESULTS: Visual field loss was associated with lower performance in the abstraction, perceptual-motor, learning, and motor domains. Significant group differences were also found on numerous individual neuropsychological tests. Based on clinical ratings, we found deficits in learning and motor functioning. No perimetry-nl subjects met criteria for MCMD or HAD, whereas 32% of perimetry-abnl subjects met diagnostic criteria for syndromic cognitive disorders (five MCMD and one HAD). In a subset of subjects who underwent a lumbar puncture, there was a trend for the perimetry-abnl group to have a higher concentration of beta2 microglobulin, a marker for central nervous system immune activation.
CONCLUSIONS: These results suggest that in some HIV-infected people reduced visual function may be caused by nonretinal disease, and perimetry may present a sensitive measure of HIV-related brain dysfunction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950603

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Effect of host genetics on incidence of HIV neuroretinal disorder in patients with AIDS.

Authors:  Efe Sezgin; Sher L Hendrickson; Douglas A Jabs; Mark L Van Natta; Richard A Lewis; Jennifer L Troyer; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

2.  Association between retinal nerve fiber layer thickness and abnormalities of vision in people with human immunodeficiency virus infection.

Authors:  Partho S Kalyani; Gary N Holland; Amani A Fawzi; Tiago E F Arantes; Fei Yu; Alfredo A Sadun
Journal:  Am J Ophthalmol       Date:  2012-01-15       Impact factor: 5.258

3.  Incidence and long-term outcomes of the human immunodefıciency virus neuroretinal disorder in patients with AIDS.

Authors:  Douglas A Jabs; Lea Drye; Mark L Van Natta; Jennifer E Thorne; Gary N Holland
Journal:  Ophthalmology       Date:  2015-01-16       Impact factor: 12.079

4.  Mitochondrial haplogroups are associated with risk of neuroretinal disorder in HIV-positive patients.

Authors:  Sher L Hendrickson; Douglas A Jabs; Mark Van Natta; Richard Alan Lewis; Douglas C Wallace; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

5.  Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group.

Authors:  William R Freeman; Mark L Van Natta; Douglas Jabs; Pamela A Sample; Alfredo A Sadun; Jennifer Thorne; Kayur H Shah; Gary N Holland
Journal:  Am J Ophthalmol       Date:  2008-01-11       Impact factor: 5.258

6.  Evaluation of hepatitis C virus as a risk factor for HIV-associated neuroretinal disorder.

Authors:  Andrea D Branch; Lea T Drye; Mark L Van Natta; Efe Sezgin; Sarah L Fishman; Douglas T Dieterich; Curtis L Meinert; Douglas A Jabs
Journal:  Clin Infect Dis       Date:  2013-09-30       Impact factor: 9.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.